Olmesartán/Amlodipino Aurovitas (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxil, the active ingredient in Olmesartán/Amlodipino Aurovitas, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension, often in combination with a calcium‑channel blocker, and is intended for adult patients. GNH USA supplies Olmesartán/Amlodipino Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartán/Amlodipino Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan/amlodipine is indicated for the management of high blood pressure within the renin‑angiotensin‑aldosterone system pathway. - Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Hypertension in patients who require combined RAAS inhibition and calcium‑channel blockade: provides additive blood‑pressure control. - Hypertension in patients who are intolerant to monotherapy with either component: offers an alternative single‑pill regimen. - Hypertension with concomitant target‑organ protection: helps reduce risk of stroke and myocardial infarction. - Resistant hypertension as adjunct therapy: may be added when blood pressure remains uncontrolled on other agents.

Olmesartan/amlodipine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Peripheral edema: mild swelling of ankles or feet. - Headache: transient tension‑type headache. - Dizziness: especially on standing. - Flushing: warm sensation, often brief. - Fatigue: generalized tiredness. - Palpitations: awareness of heartbeat.

Serious or Rare Side Effects: - Angio‑edema: rapid swelling of face, lips or throat. - Severe hypotension: symptomatic low blood pressure. - Hepatic dysfunction: elevated liver enzymes. - Renal impairment: worsening kidney function. - Myocardial infarction: rare but reported in susceptible patients. - Allergic reactions: rash, pruritus, or anaphylaxis.

When prescribing Olmesartan/amlodipine, clinicians should consider several safety aspects. - Renal function: assess baseline creatinine and monitor periodically. - Hepatic function: evaluate liver enzymes before initiation. - Electrolyte balance: watch for potassium abnormalities. - Pregnancy: avoid use; teratogenic risk is possible. - Elderly patients: start at lower dose and monitor for hypotension. - Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Olmesartan/amlodipine may interact with several medicines; awareness helps prevent clinically relevant events.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade (e.g., ACE inhibitor, another ARB): increased risk of hyperkalaemia and renal dysfunction. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise amlodipine levels.

Moderate Interactions (Monitor Closely): - Diuretics: additive blood‑pressure lowering effect, risk of hypotension. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive response and affect renal function. - Lithium: possible increase in serum lithium concentrations. - Simvastatin: amlodipine can increase statin exposure, raising myopathy risk. - Alcohol: may enhance dizziness and hypotensive effects.